Disclaimer

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arisen from or in reliance upon the whole or any part of the contents of this announcement.

Cash Dividend Announcement for Equity Issuer

Issuer name	Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Stock code	09989
Multi-counter stock code and currency	Not applicable
Other related stock code(s) and name(s)	Not applicable
Title of announcement	FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2021
Announcement date	11 April 2022
Status	New announcement
Information relating to the dividend	
Dividend type	Final
Dividend nature	Ordinary
For the financial year end	31 December 2021
Reporting period end for the dividend declared	31 December 2021
Dividend declared	RMB 0.35 per 10 share
Date of shareholders' approval	10 June 2022
Information relating to Hong Kong share register	
Default currency and amount in which the dividend will be paid	HKD amount to be announced
Exchange rate	To be announced
Ex-dividend date	14 June 2022
Latest time to lodge transfer documents for registration with share registrar for determining entitlement to the dividend	15 June 2022 16:30
Book close period	From 16 June 2022 to 20 June 2022
Record date	20 June 2022
Payment date	15 August 2022
Share registrar and its address	Tricor Investor Services Limited Level 54, Hopewell Centre 183 Queen’s Road East Hong Kong
Information relating to withholding tax	
Details of withholding tax applied to the dividend declared	To be announced

Information relating to listed warrants / convertible securities issued by the issuer	
Details of listed warrants / convertible securities issued by the issuer	Not applicable
Other information	
Other information	Not applicable
Directors of the issuer	
As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Bin; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.	